




BIOSIMILARS CONGRESS 2019

13<sup>th</sup> International Conference on

# Biosimilars and Biologics

March 18-19, 2019 Amsterdam | Netherlands



*Theme: European Biosimilars: Present Scenario & Future Prospects*

<https://Biosimilars.annualcongress.com/>

# Invitation

**Dear Colleagues,**

We are glad to announce the **13<sup>th</sup> International Conference on Biosimilars and Biologics** to be held during March 18-19, 2019 in **Amsterdam, Netherlands** from **Biosimilars Congress 2019** organized by Conference Series LLC Ltd, in collaboration with generous support and cooperation from enthusiastic academicians and editorial Board Members.

We cordially invite all the participants from all over the world who are interested in sharing their knowledge and research in the arena of Biosimilars and Biologics and Related fields. Biosimilars Congress 2019 anticipate more than 500 participants around the globe with thought provoking Keynote lectures, Oral and Poster Presentations. This is an excellent opportunity for the delegates from Universities and Institutes to interact with the world class Scientists. The intending participants can confirm their participation by registering for the conference along with your colleagues. The main theme of the conference is “Biosimilars and Biologics: Present scenario & Future prospects.


We look forward to personally welcoming you to Portugal this November

Sincerely,

**Biosimilars Congress 2019**

Organizing Committee

## Our International Open Access Journals

- 700+ Leading-edge Peer Reviewed Open Access Journals
- 21 Day Rapid Review Process
- 50000+ Editorial Board Team, 35000+ Reviewers team
- 30 Million Readers and High Visibility
- 1000+ Scientific Associations Collaborations
- 100000+  Likes
- Publication immediately after acceptance
- Quality and Quick editorial, review processing

## Salient Features

- Easy to Submit and Review Systems
- High Quality and Fast Publishing Guaranteed
- Unbiased, quality-oriented, and transparent reviews
- Truly impartial recognition of the best papers
- Feedback on the impact of every article
- Enhanced feature: Audio version of published paper
- Digital articles to share and explore
- Sharing option: Social networking enabled
- Authors, reviewers and editors are provided with scientific credits
- User friendly/feasible website articles translations across more than 50 world languages

## Our International Scientific Conferences

- More than 3000 Conferences happening across the globe
- Conferences organized in Medical, Pharma, Engineering, Science, Technology and Business.
- Continuum of education through organized scientific program
- Renowned speakers and scientists representing from 40 countries
- Highly Interactive sessions and Panel Discussions
- B2B Meetings offers perfect platform for Global Networking

## Salient Features

- Robust on-line publicity for all the speakers and organizing committee members
- Career Guidance Workshops for students and early career researchers
- Accepted Abstracts will be published in various indexed journals
- Accepted abstracts will be labeled with a Digital Object Identification Number (DOI) provided by Cross Ref
- Creation of speakers and abstracts pages in Google
- Opportunity to publish full Manuscripts in our Open Access Journals

**Special Issues : All accepted abstracts will be**

Published in Respective Supported Journals

Each Accepted abstracts will be provided with

A digital Object Identifier by  Crossref

# About Conference

The fundamental subject of 13<sup>th</sup> International Conference on Biosimilars and Biologics 2018 is “Present scenario & Future prospects”. This unique opportunity that we extend to our speakers and attendees is not being offered by any other conference organizers. Through this the abstracts and research profiles of our speakers and organizing committee members getting global visibility which is an additional feature that you would be receiving in addition to networking opportunities before, during and after the conference.

## Biosimilars Congress 2019 salient features

- Meet Academia and Industry visionaries to get inspired
- Expand your knowledge and find solutions to problems
- Knowledge, Benchmarking and Networking offered at one place
- Forge connections and for global networking
- Highly Organized and Structured Scientific programs
- Poster presentations and world class exhibitions
- Meet with new vendors and suppliers

## How Conference Series LLC Ltd Conferences differs from others?

- 3000+ Conferences across the globe in 30+ countries all through the year
- Over 25 Million+ Visitors and 20000+ Unique Visitors per conference

- Participation by Stalwarts from various international societies
- Internationally renowned speakers and scientists representation
- Career guidance for early career researchers and students
- Interesting scientific deliberations and discussions
- Perfect platform for Global Networking

## Goals

- The conference program emphasizes evidence-based practice, educational innovation, practical application, and peer to peer networking and collaboration. The goals of the conference is to provide a transformative professional development experience through
- Bringing together the world’s scientific experts to catalyze and advance scientific knowledge about Biosimilars and Biologics present the most recent industries and pharmaceutical industries which is used to develop the new ideas about the drug development and spread around the world.
- Bringing together community industry people, scientists, and policy leaders to promote and enhance programmatic collaborations to more effectively address regional, national and local responses to Elderly Population around the world and overcome barriers that limit access to care and services.

# Why to attend

## Biosimilars Congress 2019

Biosimilars Congress 2019 gives a complete 360-degree overview on Biosimilars and Biologics: Present scenario & Future prospects. Participants will leave the conference with a wealth of new information and an expanded network of contacts.

The Biosimilars is a lucrative sector owing to recent regulatory approvals and increasing opportunities. Biosimilars and Biologics are at different stages of evolution across the globe. Developing a Biosimilars demands huge investment, technical capabilities and clinical trial expertise. In order to unlock the Biosimilars potential, the industry will entail focused strategies along the whole value chain, from optimizing the clinical development program to commercialization.

Biosimilars Conferences developments are maintaining their momentum and the 2018 Biosimilars Conferences programme delves into strategic discussions regarding.

- Market and regulatory developments in the Europe and globally, enlightened by the perspective of healthcare professionals and patients experiences
- Pharmacovigilance and clinical practice - what can be learned from the emerging data?
- The impact of Biosimilars on the competitive landscape of biological products
- Developing Biosimilars & Biobetters
- Innovator Pharmaceutical Products of Biosimilars
- Current Challenges and Research trends in Biosimilars & Biologics
- Biosimilars: Pharmacovigilance and Safety
- BCS & IVIVC Based Biowaivers
- Biopharmaceutical
- Biological Medicines
- Bioequivalence Assessment
- Developing Biosimilars & Biobetters
- Generics and Biosimilars: Industrial Strategy
- Globalization of Biosimilars
- GMP, GCP, QC & R&D
- Innovation and Technology for Biosimilars Development
- Intellectual Property Rights
- Novel Drug Delivery Technologies
- Pharmacology and Drug Development
- Plant Produced Biosimilars
- Protein Biotherapeutics and Biosimilars
- Regulatory Approach for Biosimilars



### Learning objectives

- Update the participants on the current knowledge including regulatory and scientific thinking
- Deal with regulatory requirements, scientific and operational challenges
- Exchange experiences and discuss hot topics with experts
- Frame the current issues and create dialogue

### Key Features

- Meet Regulatory Expectations
- Devise Strategies
- Explore different statistical approaches to demonstrate Biosimilarity with the reference product
- Panel Discussion and Extended Q&A Sessions
- Open forum to discuss your most critical questions around Biosimilars & Biologics
- National & International Speakers
- Networking with National and International Industry stalwarts who will inspire, educate and engage in all the aspects of Biosimilars.
- Gain insights and enhance your knowledge with Biosimilars Congress 2019.
- Provides interaction with the world's well known CEO's and Directors of the Pharmaceutical companies

In this limelight, Biosimilars Congress is pleased to announce the “13th International Conference on Biosimilars and Biologics” on March 18-19, 2019 in Amsterdam, Netherlands. This conference will congregate top industry stalwarts to discuss key challenges and best practices from development to launch of Biosimilars and Biologics of market existence

Join your companions the world over focused on getting some answers concerning Biologics and Biosimilars related advances, which is your single most obvious opportunity to accomplish the greatest gathering of individuals from the Biosimilars society, coordinate shows, scatter information, meet with recurring pattern and potential specialists, make a sprinkle with new research works, and get name affirmation at this Two-day event. Broadly acclaimed speakers, the most recent research, moves, and the most momentum refreshes in Biologics and Biosimilars are indications of this gathering. Provision of information on new technologies implemented in the field of Biosimilars and a sound knowledge on the Clinical Trail development.

# *Benefits to attend*

## **Benefits to attend Biosimilars Congress 2019**

- o Keynote introduction alongside connections to excite established researchers.
- o Workshop and symposiums to achieve the biggest array of members from the Pharma/Biotech people group.
- o A wide track of exhibitors to grandstand the new and rising advancements
- o Platform to worldwide speculation group to interface with partners in Pharma/Biotech area
- o Links to the political promoting assets keeping in mind the end goal to extend your business and research organize
- o Triumph of Awards, Certificates perceives your sense of duty regarding your calling to empower the incipient research.

## **Biosimilars 2019 Benefits:**

Open board exchanges: Providing an open gathering with specialists from the scholarly world and business to talk about on current difficulties in Biosimilars and Biologics, where all participants can collaborate with the board took after by a Q&A session. Speaker and notice introductions: Providing a stage to all academicians and industry experts to share their exploration contemplations and discoveries through a discourse or a publication introduction.

Editorial executive gathering: Discussing on development and advancement of open access Bioanalysis and Biomedicine International Journals and enlisting board individuals and analysts who can bolster the diary. Round table gatherings: Providing a stage where industry experts meet scholastic specialists.

## **Business and Exhibitor Benefits:**

Over 50+ organizations and international pavilions will be exhibiting at the Biosimilars 2019 conference. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today's industry leaders. The Biosimilars Congress 2019 has everything you need, all under one roof, saving you both time and money. It is the event you cannot afford to miss!



# Market analysis

Biosimilars and Biologics have been well versed in the therapeutic areas where they have been used (e.g. rheumatology, gastroenterology) with positive benefits on access to treatment, and therefore on patient outcomes. They are about to enter cancer patient pathways where the anticipated benefits will represent a unique opportunity for re-investment in needed healthcare products and services. Market and regulatory developments in the Europe and globally, enlightened by the perspective of healthcare professionals' and patients' experiences

The impact of Biosimilars and Biologics on the competitive landscape of biological products is huge. The Biosimilars is a lucrative sector owing to recent regulatory approvals and increasing opportunities. Biosimilars are at different stages of evolution across the globe. Developing a Biosimilars demands huge investment, technical capabilities and clinical trial expertise. In order to unlock the Biosimilars potential, the industry will entail focused strategies along the whole value chain, from optimizing the clinical development program to commercialization.

## **Biosimilars Market in Europe:**

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as Biosimilars in Europe. Patent expiry of key product classes and a growing emphasis on cost-effectiveness is making governments switch to affordable alternatives.

The EMA approved four additional Biosimilars in 2016, including three Biosimilars in two new product classes: a Biosimilars of Amgen's Enbrel (etanercept) and two Biosimilars of Sanofi's Clexane (enoxaparin sodium). Etanercept is a fusion protein used to treat a variety of autoimmune disorders and enoxaparin sodium is a low-molecular-weight heparin indicated for preventing blood clots. These additional approvals bring the total of currently authorized Biosimilars in Europe to 22 and the product classes to eight. It was estimated that in 2015, Europe accounted for the largest market share of the global Biosimilars market, followed by Asia Pacific. Here is thus a tremendous opportunity for Biosimilars manufacturers. However, the development of Biosimilars drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing Biosimilars and Biologics are researching on the Biosimilars versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020. The next five years are going to be an interesting period in the Biosimilars market as a number of Biologic drugs are going to lose their exclusivity.



# *Market analysis*

## **Conclusion:**

Like most other markets, a competitive Biologics market can offer benefits to consumers by lowering prices and enhancing quality. In addition, Biosimilars have an unblemished safety track record in the E.U., where Biosimilars have been competing against biologics since 2006. Biosimilars have also proved to have a notable impact on drug prices. In the E.U., where Biosimilars are already competing with biologics, Biosimilars are sold at a 30% discount compared to branded biologic drugs.

Though Biosimilars industry faces many challenges like Patent and Legal Issues, Production Bottlenecks, Pricing Issue, Regulatory issues and lack of awareness.

In spite of the approval of 21 Biosimilars in Europe, only 18% of the physicians are aware of these similar versions of biologics. However Biosimilars industry seems to have a bright future as an alternative to patent Biologics.

Over two days, participants will dive into a dynamic programme – a crossroads between technical, scientific, market discussions and the overarching healthcare policy agenda on Biosimilars and Biologics

# About Conference

## Who will attend?

- Executives, CEO's of Industries & Organizations
- Business Development Managers
- Boss Scientific Officers
- Research and development Researchers from Biosimilars and Biologics Industries
- Educators, Associate Professors, Assistant Professors
- PhD Scholars
- Patent Attorneys
- Protected innovation Attorneys
- Speculation Analysts
- Affiliation, Association presidents and experts
- Honorable laureates in Health Care and Medicine
- Bio instruments Professionals
- Bio-informatics Professionals
- Programming improvement organizations
- Research Institutes and individuals
- Inventory network organizations
- Assembling Companies
- CRO (Contract Research Organization) and DATA administration Companies
- Preparing Institutes
- Business Entrepreneurs

# About Conference

## Trending Research Topics of Biosimilars Congress 2019

- Developing Biosimilars & Biobetters
- Intellectual Property Rights
- Innovative Approaches for Biosimilars
- Regulatory Advances in Biosimilars
- Legal Issues and BPCI Act
- Current Agency Expectations for Approval for Biosimilars
- Novel Drug Delivery Technologies
- USFDA Approved Biosimilars
- Consequences of Brexit on Biosimilars
- Biosimilars Market Strategy
- Emerging Biosimilars in Therapeutics
- Challenges in Biosimilars
- Bioequivalence Assessment
- Biological Medicines
- Biosimilars Approval to Biogenerics in Clinical Practice
- Biopharmaceutical
- BCS & IVIVC Based Biowaivers
- Pharmacovigilance Challenges and Safety
- Generic Biosimilars: Industrial Strategy
- Formulation Strategies for Follow-on Biologics
- Pharmacology and Drug Development
- Globalization of Biosimilars
- Protein Biotherapeutics and Biosimilars
- Plant Produced Biosimilars



# About Lisbon

Amsterdam :Amsterdam is the capital city. It is the most populous municipality of the Netherlands Amsterdam has a population of 851,373 within the city proper, 1,351,587 in the urban area,[and 2,410,960 in the Amsterdam metropolitan area. The city is located in the province of North Holland in the west of the country but is not its capital, which is Haarlem. The metropolitan area comprises much of the northern part of the Randstad, one of the larger conurbations in Europe, with a population of approximately 7 million.

As the commercial capital of the Netherlands and one of the top financial centers in Europe, Amsterdam is considered an alpha world city by the Globalization and World Cities (GaWC) study group. The city is also the cultural capital of the Netherlands. The Amsterdam seaport to this day remains the second in the country, and the fifth largest seaport in Europe. Famous Amsterdam residents include the diarist Anne Frank, artists Rembrandt van Rijn and Vincent van Gogh, and philosopher Baruch Spinoza. Amsterdam's main attractions, including its historic canals, the Rijksmuseum, the Van Gogh Museum, the Stedelijk Museum, Hermitage Amsterdam, the Anne Frank House, the Amsterdam Museum, its red-light district, and its many cannabis coffee shops draw more than 5 million international visitors annually It is also the world's most multicultural city with at least 177 nationalities represented.

## Tourist Attractions



# Registrations

## Academic

Only Registration: **\$599**

Package A (Registration + 1 nights' Accommodation): **\$959**

Package B (Registration + 2 nights' Accommodation): **\$1139**

## Business

Only Registration: **\$699**

Package A (Registration + 1 nights' Accommodation): **\$1059**

Package B (Registration + 2 nights' Accommodation): **\$1239**

## Student

Young Research forum: **\$329**

Student Registration: **\$249**

E-poster: **\$ 99**

## Important Dates

Abstract submission opens: **August 18, 2018**

Registration opens: **August 18, 2018**

Early bird registration: **October 24, 2018**

On spot registration: **March 18, 2019**

To register online, please visit: <https://Biosimilars.annualcongress.com/registration.php>



# Supporting Journals



## Supporting Journals



Journal of Bioequivalence & Bioavailability

Journal of Bioanalysis & Biomedicine

Journal of Pharmacovigilance

Advances in Pharmacoeconomics and Drug Safety

Clinical Pharmacology & Biopharmaceutics



# Venue & Accommodation



## Venue & Accommodation

March 18-19, 2019 Amsterdam | Netherlands

## Contact Us

Smruthi Paul

Program Director | Biosimilars Congress 2019

Conference Series LLC Ltd:

47 Churchfield Road, London, W36AY, UK

**E:** biosimilars@europemeet.com

biosimilars.pharmameetings@gmail.com

Tel: +44 203 936 3178

